miR-155-5p在急性髓系白血病预后判断中的意义研究
The significance of miR-155-5p in prognostic assessment of acute myeloid leukemia
傅甜 1吴沄桦 1王朝喆 1孙瑞婧 1姜国胜 1毕可红 2王玉芳3
作者信息
- 1. 滨州医学院基础医学院免疫学教研室,山东烟台 264003
- 2. 山东第一医科大学第一附属医院(山东省千佛山医院)血液科,山东济南 250062
- 3. 滨州医学院基础医学院免疫学教研室,山东烟台 264003;烟台市福山区人民医院检验科,山东烟台 265500
- 折叠
摘要
目的:分析外周血单个核细胞miR-155-5P表达水平在急性髓系白血病(AML)患者预后判断中的作用与预后之间的相关性.方法:采用qRT-PCR法检测诱导治疗2周后AML患者外周血单个核细胞的miRNA-155-5P表达水平.以临界值为基准分为大于临界值组和小于临界值组.按照2017ELN疗效标准确定完全缓解组(CR)和未缓解组(NR).统计分析治疗2周后外周血单个核细胞miR-155-5P表达水平在评估AML患者生存率、复发率、微小残留病、无病生存期中的意义.结果:化疗诱导治疗2周时AML患者的外周血单个核细胞的miRNA-155-5P表达水平均高于正常对照组(t=2.812,P=0.0001).完全缓解组的外周血单个核细胞miRNA-155-5P表达水平明显低于未缓解组(t=3.407,P=0.0012),复发组外周血单个核细胞miRNA-155-5P的表达水平高于非复发组(r=4.293,P＜0.0001).外周血单个核细胞miRNA-155-5P水平与无病生存期(DFS)没有明显的相关性(r=0.1600,P=0.265).但是,miRNA-155-5P大于和小于临界值两组的无病生存期具有显著性差异(t=4.54,P＜0.0001).大于临界值组的MRD发生率和NR率均低于小于临界值组(x 2=7.810,P=0.011);(x2=10.083,P=0.001).但是,miRNA-155-5P大于和小于临界值两组的CR率和复发率没有明显差异(x2=3.176,P=0.075;x2=1.539,P=0.215).外周血单个核细胞miRNA-155-5P小于临界值组的AML患者,具有更高的3年生存率和5年生存率(x2=12.84,P-0.0003;x2=10.81,P=0.0010).结论:化疗诱导治疗2周后的外周血单个核细胞miR-155-5P的表达水平是AML患者临床预后判断的重要生物学指标.
Abstract
Objective:To detect the role of miR-155-5P expression in evaluating prognosis of patients with acute myeloid leukemia(AML).Methods:The qRT PCR method was used to detect the expression ofmiRNA-155-5P in peripheral blood mononuclear cells of AML patients after 2 weeks of induction therapy.Based on the cut-off value,patients were divided into two groups,such as greater than the cut-off value and less than the cut-off value.According to the 2017 ELN efficacy criteria,the complete remission group(CR)and the non remission group(NR)were confirmed.The significance of statistical analysis of miR-155-5P expression levels in peripheral blood mononuclear cells after 2 weeks of treatment in evaluating the survival rate,recurrence rate,minimal residual disease,and disease-free survival of AML patients.Results:At 2 weeks of chemotherapy induced treatment,the expression levels of miRNA-155-5P in peripheral blood mononuclear cells of AML patients were higher than those of the normal control group(t=2.812,P=0.0001).The expression of miRNA-155-5P in peripheral blood mononuclear cells of the CR group was significantly lower than that of the NR group(t=3.407,P=0.0012),while the expression of miRNA-155-5P in peripheral blood mononuclear cells of the recurrent group was higher than that of the non recurrent group(t=4.293,P＜0.001).There was no significant correlation between miRNA-155-5P levels in peripheral blood mononuclear cells and disease-free survival(DFS)(r=0.1600,P=0.265).However,there was a significant difference in disease-free survival between the two groups with miRNA-155-5P greater than and less than the cut-off value(t=4.54,P＜0.001).The incidence of MRD and NR in the group above the critical value were lower than those in the group below the cut-off value(x2=7.810,P=0.011;x2=10.083,P=0.001).However,there was no significant difference in the CR rate and recurrence rate between the two groups with miRNA-155-5P greater than and less than the cut-off value(x2=3.176,P=0.075;x2=1.539,P=0.215).AML patients with miRNA-155-5P lower than the cut-off value group had higher 3-year and 5-year survival rates(x2=12.84,P=0.0003;x2=10.81,P=0.0010).Conclusion:The expression level of miR-155-5P in peripheral blood mononuclear cells after 2 weeks of chemotherapy induction therapy is an important biological indicator for the clinical prognosis of AML patients.
关键词
急性髓系白血病/微小残留病/完全缓解/复发/预后Key words
Acute myeloid leukemia/Minimal residual disease/Complete remission/Relapse/Prognosis引用本文复制引用
出版年
2024
NETL
NSTL
万方数据